Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 1/2011

01-08-2011

Advantages of Multiplex Proteomics in Clinical Immunology

The Case of Rheumatoid Arthritis: Novel IgXplex™ Planar Microarray Diagnosis

Authors: Peter Lea, Edward Keystone, Sasi Mudumba, Anthony Kahama, Shi-Fa Ding, Jennifer Hansen, Azar A. Azad, Sihe Wang, Deborah Weber

Published in: Clinical Reviews in Allergy & Immunology | Issue 1/2011

Login to get access

Abstract

Clinical multiplex diagnostic proteomics is the application of proteomic technologies to improve a patient’s clinical outcomes. The future holds impact potential for testing prognosis, diagnosis, and drug therapy, while monitoring efficacious treatment with qualitative and quantitative data. Multiplex clinical diagnostic use of novel biomarkers in body fluids to confirm presence and severity of clinical disease states, holds great promise for clinical use. Challenges for diagnostic clinics include awareness of proteome complexity in clinical samples, the effects of high-abundance proteins, such as albumin, that could mask detection of other and low abundance disease proteins or biomarkers. Standardized approaches to sample collection and preparation, new analytical techniques and novel algorithms for bio-statistical analysis will facilitate release of the great potential of clinical multiplex diagnostic proteomics. A sensitive RA assay has been developed for the simultaneous measurement of the three rheumatoid factors (RFs), RF-IgA, IgG, and IgM, with the option to simultaneously measure anti-cyclic citrullinated peptide (anti-CCP) IgG antibodies using IgXplex™ technology. Testing 10-μL serum samples, SQI’s multiplex microarray rheumatoid arthritis assay provides both positive/negative as well as qualitative/semi-quantitative results for anti-CCP IgG, RF-IgA, IgG, and IgM in each sample well on a 96-well microtiter-formatted microarray plate. Signal detection uses sensitive fluorescent-tagged markers captured onto planar microarray spots and read in a microarray scanner. Each result is verified with confidence confirmation technology and validating quality controls in every sample well. For an 80-RA positive patient cohort, the 4-PLEX profile sensitivity was determined at 82.5%. The specificity for the 44 RA healthy control cohort was determined at 97.7%. The multiplex data also demonstrated that a patients’ severity of disease profile, mild to severe, correlates the status of RA biomarkers to disease status.
Literature
1.
2.
Hueber W, Robinson WH (2009) Genomics and proteomics: applications in autoimmune diseases. Pharmacogenomics Personalized Medicine 2:39–48CrossRef
3.
4.
Lea P, Ling M (2008) New molecular assays for cancer diagnosis and targeted therapy. Current Opinion Molecular Therapeutics 10:251–259
5.
Cano L, Arkfeld DG (2009) Targeted synovial fluid proteomics for biomarker discovery in rheumatoid arthritis. Clinical Proteomics 5:75–102CrossRef
6.
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983PubMedCrossRef
7.
Gerszten RE, Accurso F, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo I, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB (2008) Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol 295:L16–L22PubMedCrossRef
8.
Rhigetti PG, Castagna A, Antonucci F et al (2003) The proteome: anno Domini 2002. Clin Chem Lab Med 41:425–438CrossRef
9.
Tilleman K, DeForce D, Elewaut D (2005) Rheumatology: a close encounter with proteomics. Rheumatology 44:1217–122PubMedCrossRef
10.
Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a non-redundant list developed by combination of four separate sources. Mol Cell Proteomics 3:311–326PubMedCrossRef
11.
Bjorhall K, Miliotis T, Davidsson P (2005) Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples. Proteomics 5:307–317PubMedCrossRef
12.
Anderson NL, Anderson NG, Haines LR, Hardi DB, Olafson RW, Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies. J Proteome Res 3:235–244PubMedCrossRef
13.
Elia G, Silacci M, Scheurer S, Scheuermann J, Neri D (2002) Affinity-capture reagents for protein arrays. Trends Biotechnol 20:S19–S22PubMedCrossRef
14.
Martosella J, Zolotarjova N, Liu H, Nicol G, Boyes BE (2005) Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 4:1522–1537PubMedCrossRef
15.
Morozov VN, Morozova TY (2006) Active bead-linked immunoassay on protein microarrays. Anal Chim Acta 564:40–52PubMedCrossRef
16.
Sagel SD, Chmiel JF, Konstan MW (2007) Sputum biomarkers of inflammation in cystic fibrosis lung disease. Proc Am Thorac Soc 4:406–417PubMedCrossRef
17.
Whiteaker JR, Zhao L, Zhang HY, Feng LC, Piening BD, Anderson L, Paulovich AG (2007) Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 362:44–54PubMedCrossRef
18.
Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24:971–983PubMedCrossRef
19.
Glokler J, Angenendt P (2003) Protein and antibody microarray technology. J Chromatogr B Analyt Technol Biomed Life Sci 797:229–240PubMedCrossRef
20.
SQI Diagnostic Systems, www.sqidiagnostics.com
21.
Bio-Rad Laboratories. Bio-Rad Bio-Plex System and Suspension Array Technology, accessed December 2007
22.
23.
Kersten B, Wanker EE, Hoheisel JD, Angenendt P (2005) Multiplex approaches in protein microarray technology. Expert Rev Proteomics 2:499–510PubMedCrossRef
24.
Waterboer T, Sehr P, Pawlita M (2006) Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309:200–204PubMedCrossRef
25.
US Department of Health and Human Services and Food and Drug Administration Center for Devices. Draft Guidance for Industry, Clinical Laboratories, and FDA Staff. In Vitro Diagnostic Multivariate Index Assays, accessed December 2007
26.
27.
Rai AJ, Vitzthum F (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteomics 3:409–426PubMedCrossRef
28.
Villanueva J, Philip J, Chaparro CA, Li Y, Toledo-Crow R, DeNoyer L, Fleisher M, Robbins RJ, Tempst P (2005) Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4:1060–1072PubMedCrossRef
29.
30.
Palosuo T, Tilvis R, Strandberg T, Aho K (2003) Fiaggrin related antibodies among the aged. Ann Rheum Dis 62:261–263PubMedCrossRef
31.
Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J et al (2001) Prognostic factors for radiographic damage in early rheumatoid arthritis. A multiparameter prospective study. Arthritis Rheum 44:1736–1743PubMedCrossRef
32.
Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T (2005) Prognostic laboratory markers of radiographic outcome in rheumatoid arthritis. Ann Rheum Dis 64:196–201PubMedCrossRef
33.
Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, Szanto S, Szues G, Szekanecz Z (2009) Anti citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev [Epub ahead of print]: May 7, in press
34.
van Boekel MA, Vossenaar ER, van den Hoogen FH, van Venrooij WJ (2002) Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arth Res 4:87–93CrossRef
35.
Steiner G, Smolen JS (2002) Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 4:S1–S5PubMedCrossRef
36.
Marcelletti JF, Nakamura RM (2003) Assessment of serological markers associated with rheumatoid arthritis: diagnostic autoantibodies and conventional disease activity markers. Clin Appl Immunol Rev 4:109–123CrossRef
37.
Zendman AJW, van Venrooij WJ, Pruijn GJM (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 45:20–25PubMedCrossRef
38.
Schellekens GA, Visser H, de Jong BA et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155–163PubMedCrossRef
39.
Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680PubMedCrossRef
40.
Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R (2001) Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 47(6):1089–1093PubMed
41.
Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning HMT, Habibuw MR, Vandenbroucke JP, Dijkmans BAC (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50:380–386PubMedCrossRef
42.
Raza K, Breese M, Nightingale P et al (2005) Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol 32:231–238PubMed
43.
O’Connor TET, Morris A, Smith K, Ricks C, Lea P (2009) Automated Quantitative multiplexed microarray platform. IVD Technology 15(9):43–49
44.
Berglin E (2006) Predictors of disease onset and progression in early rheumatoid arthritis. A Clinical, Laboratory and Radiological Study. Umea University Medical Dissertations: ISBN 91-7264-003-0. Dept Public Health and Clinical Medicine, Rheumatology, Umea, Sweden
45.
Atzeni F, Sarzi-Puttini P, Dell’ Aqua D, de Portu S, Cecchini G, Cruini C, Carabba M, Meroni PL (2006) Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arth Res & Ther 8:R3CrossRef
46.
Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis & Rheumatism 46:357–365CrossRef
47.
Bossuyt X (2009) Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev 8:543–548PubMedCrossRef
48.
Rantapaa-Dahlqvist S, deJong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis & Rheumatism 48:2741–2749CrossRef
49.
Vencovsky J, Sedova L, Kafkova J, Gatterova J, Pesakova V, Ruzickova S (2003) Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 62:427–430PubMedCrossRef
50.
Feng Y, Ke X, Ma R, Chen Y, Hu G, Liu F (2004) Parallel detection of autoantibodies with microarrays in rheumatoid diseases. Clin Chem 50:416–422PubMedCrossRef
51.
Vallbracht I, Rieber J, Oppermann M, Foerger F, Siebert U, Helmke K (2004) Diagnostic and clinical value of anti-citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 63:1079–1084PubMedCrossRef
52.
Hoffman IEA, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, Lebeer K, De Clercq L, Schatteman L, Poriau S, Mielants H, Veys EM, De Keyser F (2005) Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 51:261–265PubMedCrossRef
53.
Hueber W, Kidd BA, Tomooka BH, Lee BJ, Bruce B, Fries JF, Sonderstup G, Monach P, Drijfhout JW, van Venrooij WJ, Utz PJ, Genovese MC, Robinson WH (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52:2645–2655PubMedCrossRef
54.
Roennelid J, Wick MC, Lampa J, Lindblad S, Nordmark B, Klareskog L, van Vollenhoven RF (2005) Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis 64:1744–1749CrossRef
55.
Cruyssen BV, Cantaert T, Nogueira L, Clavel C, De Rycke L, Dendoven A, Sebag M, Deforce D, Vincent C, Elewaut D, Serre G, De Keyser F (2006) Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arth Res & Ther 8:R122CrossRef
56.
Maddison P, Huey P (2006) Rheumatic diseases. Serological aids to early diagnosis. Top Rev 8:1–8
57.
Pedersen M, Jacobsen S, Klarlund M, Pedersen BV, Wiik A, Wohlfart J, Frisch M (2006) Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arth Res & Ther 8:R133CrossRef
58.
Nikolaisen C, Rekvig O, Nossent HC (2007) Diagnostic impact of contemporary biomarker assays for rheumatoid arthritis. Scandinavian J Rheumatol 36:97–100CrossRef
59.
Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa G, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007) Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 146:797–808PubMed
60.
Dos Anjos LME, Pereira IA, d’Orsi E, Seaman AP, Burlingame RF, Morato EF (2009) A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis. Clin Rheumatol 28:153–158PubMedCrossRef
61.
Tedesco A, D’Agostino D, Soriente I, Amato P, Piccoli R, Sabatini P (2009) A new strategy for the early diagnosis of rheumatoid arthritis:A combined approach. Autoimmunity Reviews 233–237
62.
Shoenfeld Y, Gershwin ME (2008) Whither autoimmunity: the lessons of Anti-CCP and B cell depletion. Clin Rev Allergy Immunol 34:1–3PubMedCrossRef
63.
Wiik AS (2003) Appropriateness of autoantibody testing in clinical medicine. Clin Chim Acta 333:177–180PubMedCrossRef
64.
Villalta D, Tozzoli R, Tonutti E, Bizzaro N (2007) The laboratory approach to the diagnosis of autoimmune diseases: is it time to change? Autoimmunity Reviews 6:359–365PubMedCrossRef
65.
Talapatra A, Rouse R, Hardiman G (2002) Protein microarrays: challenges and promises. Pharmacogenomics 3:1–10CrossRef
66.
Anderson NL (2005) The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol Cellu Proteomics 4:1441–1444CrossRef
67.
Hueber W, Lee BJ, Genovese M, van Venrooij W, Steinman L, Putz PJ, Robinson WH (2003) Multiplex autoantibody profiling using ‘synovial proteome’ microarrays identifies citrulline-modified peptides as major targets of the autoimmune response in rheumatoid arthritis. Arth Res & Ther 5:99CrossRef
68.
Tjalsma H, Schaeps RM, Swinkels SW (2008) Immunoproteomics: from biomarker discovery to diagnostic applications. Proteomics Clin Appl 2:167–180PubMedCrossRef
69.
Rashtak S, Ettore MW, Homburger HA, Murray JA (2008) Combination testing for antibodies in the diagnosis of celiac disease: comparison of multiplex immunoassay and ELISA methods. Aliment Pharmacol Ther 28:805–813PubMedCrossRef
70.
Hartman M, Schrenk M, Doettinger A, Nagel S, Roeraade J, Joos TO, Templin MF (2008) Expanding assay dynamics: a combined competitive and direct assay system for the quantification of proteins in multiplexed immunoassays. Clin Chem 54:956–963CrossRef
71.
Plebani M, Pittoni M, Celadin M, Bernadi D, Mion MM (2009) Recent advances in diagnostic technologies for autoimmune diseases. Autoimmunity Reviews 8:238–243PubMedCrossRef
72.
Ellington AA, Kullo IJ, Bailey KR, Klee GG (2009) Measurement and quality control issues in multiplex protein assays: a case study. Clinica Chemistry 55:1092–1099CrossRef
73.
74.
Simon A, Girard-Egrot A, Sauter F, Pudda C, Picollet D’Hahan N, Blum L, Chatelain F, Fuchs A (2007) Formation and stability of a suspended bio-mimetic lipid bilayer on silicon submicrometer-sized pores. J Colloid Interface Science 308:337CrossRef
75.
Pierangeli SS, Harris EN (2005) Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 357:17–33PubMedCrossRef
76.
Merkel P, Chang Y, Pierangeli SS, Harris EN, Polisson RP (1999) Comparisons between the standard anticardiolipin antibody test and a new phospholipids test in patients with connective tissue diseases. J Rheumatol 26:591–596PubMed
77.
Koike T, Bohgaki M, Amengual O, Atsumi T (2007) Antiphospholipid antibodies: lessons from the bench. J Autoimmunity 28:129–133CrossRef
78.
Wong RCW, Favaloro EJ, Adelstein S, Baumgart K, Bird R, Brighton TA, Empson M, Gillis D, Hendle MJ, Laurent R, Mallon D, Pollock W, Smith S, Steele RH, Wilson RJ (2008) Consensus guidelines on ant-beta 2 glycoprotein I testing and reporting. Pathology 40:58–63PubMedCrossRef
79.
Lieby P, Poindron V, Roussi S, Klein C, Knapp A-M, Garaud J-C, Cerutti M, Martin T, Pasquali J-L (2008) Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack. Blood 104:1711–1715CrossRef
80.
Charles PJ (2004) Multiplex analysis of antinuclear antibodies by flow cytometry using FIDIS. Arthritis Res Ther 6(Suppl 1):8CrossRef
81.
Gonzalez C, Garcia-Berrocal B, Talavan T, Casas ML, Navajo JA, Gonzalez-Buitrago JM (2005) Clinical evaluation of a microsphere bead-based flow cytometry assay for the simultaneous determination of anti-thyroid peroxidase and anti-thyroglobulin antibodies. Clin Biochem 38:966–972PubMedCrossRef
82.
Tozzoli R, Villalta D, Kodermaz G, Bagnasco M, Tonutti E, Bizarro N (2006) Autoantibody profiling of patients with autoimmune thyroid disease using a new multiplexed immunoassay method. Clin Chem Med 44:837–842CrossRef
83.
Martins TB, Burlingame R, von Muehlen CA, Jaskowski TD, Litwin CM, Hill HR (2004) Evaluation of multiplexed fluorescent microsphere immunoassay for detection of autoantibodies to nuclear antigens. Clin Diagn Lab Immunol 11:1054–1059PubMed
84.
Binder SR, Genovese MC, Merrill JT, Morris RI, Metzger AL (2005) Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol 12:1353–1357PubMed
85.
Grimes DA, Schulz KF (2005) Refining clinical diagnosis with likelihood ratios. Lancet 365:1500–1505PubMedCrossRef
86.
Kaul R, Johnson K, Scholz H, Marr G (2009) Performance of the BioPlex™ 2200 autoimmune vasculitis kit. Autoimmunity Reviews 8:224–227PubMedCrossRef
87.
Lidar M, Lipschitz N, Langevitz P, Barzilai O, Ram M, Porat-Katz B-S, Pagnoux C, Guilpain P, Sinico RA, Radice A, Bizarro N, Damoiseaux J, Tervaert JWC, Martin J, Guillevin L, Bombardieri S, Shoenfeld Y (2009) Infectious serologies and autoantibodies in Wegener’s granulomatosis and other vasculitides: novel associations disclosed using the Rad BioPlex 2200. Ann N Y Acad Sci 1173:649–657PubMedCrossRef
88.
Hintzen C, Quaiser S, Pap T, Heinrich PC, Hermanns HM (2009) Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis. Arth Rheum 60:2102–2112CrossRef
89.
Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW (2009) The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arth Rheum 60:2390–2401CrossRef
90.
Marta M, Meier UC, Lobell A (2009) Regulation of autoimmune encephalomyelitis by toll-like receptors. Autoimmun Rev 8:506–509PubMedCrossRef
91.
Xiao X, Ma B, Dong B, Zhao P, Tai N, Chen L, Wong FS, Wen L (2009) Cellular and humoral immune responses in the early stages of diabetic nephropathy in NOD mice. J Autoimmun 32:85–93PubMedCrossRef
92.
Enghard P, Humrich JY, Rudolph B, Rosenberger S, Biesen R, Kuhn A, Manz R, Hiepe F, Radbruch A, Burmester GR, Riemekasten G (2009) CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arth Rheum 60:199–206CrossRef
93.
Kanazawa Y, Shimada A, Oikawa Y, Okubo Y, Tada A, Imai T, Miyazaki J, Itoh H (2009) Induction of anti-whole GAD65 reactivity in vivo results in disease suppression in type 1 diabetes. J Autoimmun 32:104–109PubMedCrossRef
94.
Yang K, Vega JL, Hadzipasic M, Schatzmann Peron JP, Zhu B, Carrier Y, Masli S, Rizzo LV, Weiner HL (2009) Deficiency of thrombospondin-1 reduces Th17 differentiation and attenuates experimental autoimmune encephalomyelitis. J Autoimmun 32:94–103PubMedCrossRef
95.
Youinou P, Jamin C (2009) The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 32:206–210PubMedCrossRef
96.
Motrich RD, van Etten E, Depovere J, Riera CM, Rivero VE, Mathieu C (2009) Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J Autoimmun 32:140–148PubMedCrossRef
97.
Adamus G, Karren L (2009) Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J Autoimmun 32:133–139PubMedCrossRef
98.
Mendes D, Correia M, Barbedo M, Vaio T, Mota M, Goncalves O, Valente J (2009) Behcet’s disease—a contemporary review. J Autoimmun 32:178–188PubMedCrossRef
99.
Chretien P, Chousterman M, Abd Alsamad I, Ozenne V, Rosa I, Barrault C, Lons T, Hagege H (2009) Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. J Autoimmun 32:201–205PubMedCrossRef
100.
Karosi T, Szekanecz Z, Sziklai I (2009) Otosclerosis: an autoimmune disease? Autoimmun Rev, in press
101.
Czompoly T, Simon D, Czirjak L, Nemeth P (2009) Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 8:692–696PubMedCrossRef
102.
Sa MJ (2009) Acute transverse myelitis: a practical reappraisal. Autoimmun Rev, in press
103.
Invernizzi P, Pasini S, Selmi C, Gershwin ME, Podda M (2009) Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 33:12–16PubMedCrossRef
104.
Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz de Rabago E, Sanchez-Ramon S, Rodriguez-Mahou M, Paravisini A, Monteagudo I, Gonzalez CM, Garcia-Castro M, Casas MD, Carreno L (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arth Rheum 61:419–424CrossRef
Metadata
Title
Advantages of Multiplex Proteomics in Clinical Immunology
The Case of Rheumatoid Arthritis: Novel IgXplex™ Planar Microarray Diagnosis
Authors
Peter Lea
Edward Keystone
Sasi Mudumba
Anthony Kahama
Shi-Fa Ding
Jennifer Hansen
Azar A. Azad
Sihe Wang
Deborah Weber
Publication date
01-08-2011
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 1/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8189-z

Other articles of this Issue 1/2011

Clinical Reviews in Allergy & Immunology 1/2011 Go to the issue

ReviewPaper

Intranasal Steroids in the Treatment of Allergy-Induced Rhinorrhea

ReviewPaper

Chemokines and Their Receptors in the Allergic Airway Inflammatory Process

OriginalPaper

Identification of European Allergy Patterns to the Allergen Families PR-10, LTP, and Profilin from Rosaceae Fruits

OriginalPaper

A Meta-analysis of the Association of Exhaled Carbon Monoxide on Asthma and Allergic Rhinitis

OriginalPaper

Novel Challenges for the Allergist

ReviewPaper

Therapeutic Approaches in Hereditary Angioedema
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits